Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy

HIV Medicine

Volumn 8, Issue 4, 2007, Pages 220-225

  Van Lunzen, Jan ^a   Liess, H ^b,c   Arasteh K ^d   Walli, R ^e   Daut, B ^e   Schurmann D ^f  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c VERTEX PHARMACEUTICALS   (United States)

^d Vivantes Auguste Viktoria Klinikum   (Germany)

^e GLAXOSMITHKLINE   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gastric acid reducing agents; Protease inhibitors based HAART; Proton pump inhibitors

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; NON PRESCRIPTION DRUG; OMEPRAZOLE; PANTOPRAZOLE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DRUG INTERMITTENT THERAPY; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; GERMANY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTACIDS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; QUESTIONNAIRES;

EID: 34247886170     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00456.x     Document Type: Article

References (22)

1. Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
2. Liu H, Miller LG, Hays RD et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 2006; 41: 315-322.
3. Sherer RD Jr, Fath MJ, Da Silva BA, Nicolau AM, Miller NL. The importance of potency and durability in HIV patient antiretroviral therapy preferences: A telephone survey. AIDS Patient Care STDs 2005; 19: 794-802.
4. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708-712.
5. Descamps D, Flandre P, Calvez V et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team). J Am Med Assoc 2000; 283: 205-211.
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma concentrations can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-75.
7. Sax PE, Gathe JC Jr. Beyond efficacy: The impact of combination antiretroviral therapy on quality of life. AIDS Patient Care STDs 2005; 19: 563-576.
8. van Heeswijk RPG, Sabo JP, Cooper C et al. The pharmacokinetic interactions between tipranavir/ritonavir 500/200 mg bid and atorvastatin, antacid and CYP3A4 in healthy adult volunteeers. 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, April 2004 [Abstract 35].
9. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetic effect of omeprazole on atazanavir co-administered with ritonavir in healthy subjects. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005 [Abstract 658].
10. EMEA Public Statement. Important New Pharmacokinetic Data Demonstrating that REYATAZ (atazanavir sulfate) Combined with NORVIR (ritonavir) and Omeprazole should not be Co-administered. EMEA/202649/2004 0.1. http://www.emea.eu.int./pdfs/human/press/pus/20264904en.pdf, 2004.
11. Luber A, Garg V, Gharakhanian S, Vertex HIV Program Team. Survey of medication used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Abstract 206].
12. Guessant S, Le Camus C, Lang JM. Survey on the gastric acid-modifying medications use in HIV-infectd (HIV+) patients on antiretroviral (ARV) treatment in France. 10th EACS Conference. Dublin, Ireland, November 2005 [Abstract PE4.6/1].
13. Khanlou H, Farthing C. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. J Acquir Immune Defic Syndr 2005; 39: 503.
14. Luber AD. Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes. AIDS Read 2005; 15: 698-700.
15. Guiard-Schmid JB, Poirier JM, Bonnard P et al. Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir. AIDS 2005; 19: 1937-1938.
16. Guiard-Schmid JB, Poirier JM, Bonnard P, Meynard JL. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. J Acquir Immune Defic Syndr 2006; 41: 393-394.
17. Khanlou H, Louie S, Farthing C. Response to: Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. J Acquir Immune Defic Syndr 2006; 41: 394.
18. Furtek KJ, Crum NF, Olson PE, Wallace MR. Proton pump inhibitor therapy in atazanavir-treated patients: Contraindicated? J Acquir Immune Defic Syndr 2006; 41: 394-396.
19. Tomilo DL, Smith PF, Ogundele AB et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 2006; 26: 341-346.
20. Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy 2006; 26: 511-514.
21. Mocroft A, Phillips AN, Ledergerber B et al. for the Eurosida Study Group. Relationship between antiretrovirals used as part of a HAART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20: 1141-1150.
22. Robert Koch Institut. Epidemiologisches Bulletin: Sonderausgabe A. Robert Koch Institute, Berlin, 2006: 1-16 (in German).